The transgenic construct contains a full length human dystrophin gene modified by the deletion of the H2 domain and deletion of spectrin-like repeat 4 through repeat 19 and the C-terminus to generate a micro-dystrophin cDNA (DH2-R19) under the control of the human skeletal alpha 1 actin (ACTA1) promoter. (J:146281)